HTX Spins Off New Company (Australia)
This article was originally published in PharmAsia News
Australian diagnostics company, HealthLinx, is in the process of setting up a new subsidiary focused on drug research and development. The subsidiary, called Proaegis Biosciences, is designed to further treatments for acute respiratory distress syndrome and ulcerative colitis. Already HealthLinx has in-licensed patents for drugs to treat each condition to Proaegis. The treatments, CR014 and Follistatin, are expected to enter Phase I clinical trials soon. HealthLinx plans to retain a 36 percent interest in the new company. In the meantime, the company has already raised $1 million of the $5 million it is hoping to retain through initial investors. (Click here for more
You may also be interested in...
Pink Sheet reporters and editors look at the UK MHRA’s surprising approval of the Pfizer/BioNTech coronavirus vaccine, as well as the US reaction, and discuss President-elect Joe Biden’s potential US FDA commissioner nominees.
Divesting the heart valve division will allow LivaNova to focus more resources on its neuromodulation, cardiopulmonary and circulatory support businesses.
The US FDA tells manufacturers in two recent warning letters to get to the root cause of contamination problems and take a more proactive approach to cleaning and equipment maintenance.